Lunai Bioworks LNAI
Nasdaq · Pharmaceutical Preparations$0.16−30.20%Oct 29 close · Databento
LNAI Wire Story Reactions & EOD Technical StudyDaily closes (Databento EOD) pinned with every AlgoThesis Wire story (dot colour = next trading day close) and SEC filing
Oct 29, 2026CLOSE $0.161D −30.20%3M −93.10%SMA20 $0.74SMA50 $1.61RSI(14) 13.4
RSI (14, Wilder EOD) · 70 Overbought / 30 OversoldRSI 13.4
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
1 story has a settled next close so far (1 on the Wire). The record starts speaking at three.
The numbers
fiscal 2026, as filed with the SEC · 66-metric EOD snapshot via DatabentoRevenue$51,992 +58.7%
True FCF (ex-SBC)$-5.9M +52.1%
Rule of 40-10114.9%
Operating margin-16729.4%
FCF Margin-10173.6%
EPS, diluted$-1.06 +98.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$-1.05
EPS (diluted)$-1.06
Compounder & Returns
Rule of 40-10114.9%
ROIC—
Cash ROIC (CROIC)—
GP / Assets—
ROE39.5%
ROA-35.8%
Gross Margin—
Oper. Margin-16729.4%
Net Margin-6852.0%
FCF Margin-10173.6%
True FCF Margin-11386.0%
Quality & Dilution
Cash Conversion—
Accrual Ratio+17.4%
SBC % of FCF—
SBC % of Rev1212.5%
Reinvest. Rate—
Sales Growth Y/Y+58.7%
Sales 3Y CAGR—
EPS Growth Y/Y+98.8%
FCF Growth Y/Y+52.1%
FCF 3Y CAGR—
Share Change Y/Y+62.9%
Balance Sheet & Scale
Revenue (FY)$51,992
Gross Profit (FY)—
Oper. Income (FY)$-8.7M
GAAP Net Income$-3.6M
True FCF (ex-SBC)$-5.9M
Cash & Equiv$1.7M
Total Debt$204,111
Net Cash (Debt)$1.5M
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio0.115.03M sh
Price & Technicals (EOD)
Perf Week−64.94%
Perf Month−88.79%
Perf Quarter−91.51%
Perf Half Y−50.06%
Perf YTD−51.53%
SMA 20 Dist−77.65%$0.74
SMA 50 Dist−89.74%$1.61
SMA 100 Dist−92.40%$2.17
Window High−96.17%$4.30
Window Low0.00%$0.16
RSI (14) · Vol13.4231%v
Income Distribution & Cash Flow ConversionHow every dollar of LNAI revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Where Every $100 of Revenue Goes (FY2026)
Cost of Revenue (COGS)$5,275 ($10.1 / $100)
R&D Reinvestment$24,518 ($47.2 / $100)
Operating Expenses$8.7M ($100.0 / $100)
Tax & Non-Operating$0 ($0.0 / $100)
Net Profit Kept$-3.6M ($0.0 / $100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2026)
GAAP Net Income$-3.6M (-6852.0% margin)
Operating Cash Flow (OCF)$-5.3M(-10171.2% of rev)
Less: Capital Expenditures−$1,238(2.4% of rev)
Standard Free Cash Flow (FCF)$-5.3M(-10173.6% margin)
Less: Stock-Based Comp (SBC)−$630,389
True FCF (Owner Cash ex-SBC)$-5.9M(-11386.0% of rev)
Revenue by fiscal year
Operating leverage — margins
GrossOperatingNet
| Line Item (USD) | FY2012 | FY2012 | FY2013 | FY2026 | YoY Δ | 3Y CAGR | Trend |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $0 | $62,806 | $32,768 | $51,992 | +58.7% | — | |
| Cost of Revenue (COGS) | — | $64,385 | $109,299 | $5,275 | −95.2% | −71.4% | |
| Gross Profit | — | $-1,579 | $-76,531 | — | — | — | |
| Research & Development (R&D) | — | — | — | $24,518 | — | — | |
| Total Operating Expenses | — | $1.9M | $1.7M | $8.7M | +426.3% | +113.3% | |
| Operating Income (EBIT) | — | $-1.9M | $-1.7M | $-8.7M | −400.2% | — | |
| Interest Expense | — | $704,911 | $652,703 | $235,074 | −64.0% | −42.3% | |
| Income Tax Expense | $0 | — | — | $1,406 | — | — | |
| GAAP Net Income | $-29,945 | $-2.4M | $-2.1M | $-3.6M | −65.9% | — | |
| Diluted EPS | $0.00 | $-0.46 | $-0.40 | $-1.06 | −165.0% | — | |
| Diluted Shares | — | — | — | 3.4M | — | — | |
| Balance Sheet | |||||||
| Cash & Equivalents | $1.7M | $4,381 | $18,794 | $1.7M | +9018.1% | +0.0% | |
| Total Current Assets | $13,555 | $105,930 | $141,492 | $2.0M | +1339.2% | +431.6% | |
| Total Assets | $13,555 | $362,864 | $450,467 | $9.9M | +2107.0% | +801.8% | |
| Total Current Liabilities | $27,235 | $2.1M | $2.1M | $18.9M | +785.9% | +785.5% | |
| Total Debt (Short + Long Term) | $204,111 | $204,111 | $1.5M | $204,111 | −86.0% | +0.0% | |
| Total Liabilities | $19.0M | $4.7M | $2.1M | $19.0M | +788.5% | +0.0% | |
| Stockholders' Equity | $-13,680 | $-4.4M | $-1.7M | $-9.0M | −435.9% | — | |
| Net Cash / (Net Debt) | $1.5M | $-199,730 | $-1.4M | $1.5M | +205.0% | +0.0% | |
| Invested Capital | $-1.5M | $-4.2M | $-246,962 | $-10.5M | −4165.6% | — | |
| Cash Flow & Capital Allocation | |||||||
| Operating Cash Flow (OCF) | $-24,945 | $-933,013 | $-2.1M | $-5.3M | −148.2% | — | |
| Depreciation & Amortization (D&A) | — | $56,600 | $38,297 | $93,522 | +144.2% | +28.5% | |
| Stock-Based Compensation (SBC) | — | — | — | $630,389 | — | — | |
| Capital Expenditures (CapEx) | — | — | — | $1,238 | — | — | |
| Free Cash Flow (FCF) | — | — | — | $-5.3M | — | — | |
| True FCF (ex-SBC Owner Cash) | — | — | — | $-5.9M | — | — | |
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what LNAI did at the next close after each storyOct 22
Lunai Bioworks plans Nasdaq delisting after listing compliance notice
−37.32%PR Newswire · 7:00 PM ET
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.